Research article · 26 Apr 2023
Conference abstract
BIOEQUIVALENCE IN TRANS DERMALS
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
T ransdermal drug delivery system has been in existence for a long time. In the past, the most commonly applied systems were topically applied creams and ointments for dermatological disorders. Now there are novel patches in various therapeutic areas. The Transdermal Drug Delivery System (TDDS) offers several advantages over the traditional orals and injectables. It is a controlled release of drug, does not require frequent dose, is painless and most importantly does not undergo first pass metabolism. With such advantages, the Pharmaceutical industry is developing several TDDS for drugs used in elderly, children, chronic illness etc. Bioavalability with transdermals poses certain challenges such as variability, physicological differences and formulation differences. The patches also pose problems such as skin sensitization and irritability. One of the important aspect is adhesivity of the patch. Considering the various factors affecting the bioavailability of transdermals, the regualtory has defined certain guidelines for the conduct of such studies. The bioequivalence of a TDDS in comparison to the innovator's product should usually be assessed after single dose as well as after multiple dose administration; ? The site of application for the bioequivalence study should be in the same body area for both test and reference product; ? As patches are often highly variable drug products it is recommended to assess the intra-individual variability and, in particular, to determine the influence of biopharmaceutical performance on this variability by conducting a study with replicate design; ? If TDDS with different release mechanism (reservoir versus matrix) are compared a study using replicate design is required to investigate subject by formulation interaction; ? both products should demonstrate the same or less degree of local irritation, adhesiveness to the skin, phototoxicity (phototoxic potential), sensitization and similar systemic adverse events profile compared to the reference product; ? Bioequivalence is assessed using the same main characteristics and statistical procedures as for the prolonged release formulations PDF HTML
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Designing the novel polymeric-based trans-dermal drug delivery systems
Conference abstract · 7 Nov 2016
Dermal Open Flow Microperfusion (dOFM) for the bioequivalence assessment of topical products based on skin PK
Conference abstract
Application of dermal microdialysis for the determination of bioavailability/ bioequivalence of topical drug products not intended for systemic circulation
Conference proceeding · 2019
2020 Conference Announcement on Bioavailability and Bioequivalence, November 26-27, 2020 | Istanbul, Turkey
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Charu Gautam”
